BioPharmSignal logoBioPharmSignal

Biotech News

Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

Enanta Pharmaceuticals (ENTA)Enanta PharmaceuticalsConference / presentation

WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 3, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management will participate in a fireside

Related news

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

XFORX4 Pharmaceuticals2026-05-27 11:00 EST

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

CLDXCelldex Therapeutics2026-06-10 20:01 EST

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

GPCRStructure Therapeutics2026-06-05 20:05 EST

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

View all latest news

Enanta Pharmaceuticals

Small-Molecule Research Platform Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment. EDP-978 KIT Inhibitor EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic...

Recent company news

ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-11 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

Stock data

Close
13.34 USD
Market cap
349.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States